French Neuroimaging Leader Iconeus Launches U.S. Subsidiary to Accelerate Preclinical Functional Ultrasound Adoption

French neuroimaging firm Iconeus expands to the U.S. with the launch of Iconeus Inc., supporting the adoption of functional ultrasound in preclinical research.

By: AXL Media

Published: Mar 14, 2026, 5:41 AM EDT

Source: Information for this report was sourced from Iconeus

Strategic Expansion into the North American Neuroscience Ecosystem

The establishment of Iconeus Inc. represents a significant milestone for the Paris-based neuroimaging firm as it seeks to formalize its presence in the United States. By creating a local entity, Iconeus aims to provide direct support and closer collaboration for its growing list of American clients, which already includes prestigious universities and national research centers. CEO and Co-Founder Ludovic Lecointre emphasized that the United States remains home to one of the most active neuroscience research environments in the world. This move is designed to transition the company from a remote supplier to a local partner capable of accelerating the integration of functional ultrasound into daily laboratory workflows.

Advanced Imaging Tools for Real-Time Brain Activity

At the heart of the company’s expansion is its proprietary fUS technology, which allows for the imaging of cerebral blood flow and microvasculature with high sensitivity and resolution. Unlike traditional imaging modalities, fUS provides researchers with the ability to observe whole-brain activity in real time, even in awake or moving subjects. This capability is critical for studying task-induced activation and functional connectivity in preclinical models. By establishing a domestic base, Iconeus ensures that U.S. researchers have immediate access to technical expertise and the latest hardware advancements, such as their MultiArray probes designed for volumetric 3D imaging.

Strengthening Partnerships with Academic and Industrial Research

The new U.S. entity is positioned to work alongside a diverse range of stakeholders, from academic laboratories and research institutes to contract research organizations (CROs) and major pharmaceutical companies. These partnerships are vital for the development of new therapies targeting neurological disorders. Functional ultrasound serves as a high-speed tool for evaluating how experimental drugs influence brain neurovasculature and connectivity. The local presence will facilitate more frequent live demonstrations, training sessions, and collaborative research programs, ensuring that the technology is utilized to its full potential in drug discovery and basic science.